"World's first! MSD Merck's blockbuster new drug approved, priced at $14,000 per dose"
Is there finally a drug that can cure pulmonary arterial hypertension, known as a "terminal illness"?
On March 26 local time, Merck announced that one of its new drugs has been approved by the FDA for the treatment of adult pulmonary arterial hypertension (PAH). The drug, administered via fixed subcutaneous injection every three weeks, can increase patients' exercise tolerance, alter the disease progression, and reduce the risk of clinical deterioration events in pulmonary arterial hypertension.
A researcher involved in the drug development stated:
"This approval is an important milestone because it provides healthcare providers with a new pathway for PAH treatment options."
Currently, the drug is priced at $14,000 (approximately RMB 100,000) in the U.S., with an annual cost of about $243,000 (approximately RMB 1.75 million).
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
